LVTX - Lava Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-32.96M

Cash

94.57M

Avg Qtr Burn

-7.941M

Short % of Float

0.44%

Insider Ownership

28.72%

Institutional Own.

32.53%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LAVA-1207 Details Cancer, Solid tumor/s, Castration-resistant prostate cancer, Prostate cancer, Prostate disease	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SGN-EGFRd2 (LAVA-1223) Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LAVA-051 ( gamma-delta bsTCE targeting CD1d-expressing tumors) Details Solid tumor/s, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.